Why the study?
Do SGLT2 inhibitors improve symptoms and biomarkers in diabetic patients with drug-refractory advanced heart failure?
Do SGLT2 inhibitors improve symptoms and biomarkers in diabetic patients with drug-refractory advanced heart failure?
SGLT2 inhibitors may be safe and effective for improving symptoms and biomarkers in diabetic patients with drug-refractory advanced heart failure, particularly those with right-sided heart failure.
Suggests possible SGLT2i benefit in refractory HF; hypothesis-generating and requires randomized trials before practice change.
BACKGROUND: This study aimed to investigate the effect and safety of sodium glucose cotransporter 2 inhibitors (SGLT2-Is) in patients with drug-refractory heart failure (HF). METHODS AND RESULTS: In 12 diabetic patients with advanced HF, SGLT2-Is were added to the treatment regimen. At 6 months after administration, improvements in New York Heart Association class and reduction in B-type natriuretic peptide levels were observed, in particular in patients with high right atrial pressure. During follow-up, they had neither cardiac events nor adverse side effects. CONCLUSIONS: SGLT2-Is may be useful and safe in diabetic patients with drug-refractory HF, in particular accompanied by right-sided HF.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: